Assetmark Inc. Boosts Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Assetmark Inc. increased its position in shares of Natera, Inc. (NASDAQ:NTRA) by 2.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,353 shares of the medical research company’s stock after purchasing an additional 150 shares during the period. Assetmark Inc.’s holdings in Natera were worth $933,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in NTRA. Itau Unibanco Holding S.A. purchased a new position in Natera in the second quarter valued at about $28,000. Quarry LP boosted its position in Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after acquiring an additional 190 shares during the last quarter. GAMMA Investing LLC boosted its position in Natera by 50.0% during the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after acquiring an additional 108 shares during the last quarter. Tobam acquired a new stake in Natera during the second quarter worth approximately $74,000. Finally, DekaBank Deutsche Girozentrale acquired a new stake in Natera during the first quarter worth approximately $83,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Stock Performance

Natera stock opened at $146.06 on Friday. Natera, Inc. has a 12-month low of $52.01 and a 12-month high of $167.79. The company has a market capitalization of $19.28 billion, a price-to-earnings ratio of -82.99 and a beta of 1.53. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.01. The firm’s fifty day moving average price is $127.38 and its 200 day moving average price is $115.46.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.31. The firm had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm’s quarterly revenue was up 63.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.95) EPS. On average, research analysts forecast that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on NTRA. Leerink Partners raised their target price on shares of Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Piper Sandler restated an “overweight” rating and set a $150.00 target price on shares of Natera in a research report on Friday, September 13th. Sanford C. Bernstein raised their target price on shares of Natera from $125.00 to $135.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. The Goldman Sachs Group raised their target price on shares of Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Finally, Stephens reaffirmed an “overweight” rating and set a $125.00 price target on shares of Natera in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $137.65.

Insiders Place Their Bets

In related news, CEO Steven Leonard Chapman sold 5,024 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $128.48, for a total value of $645,483.52. Following the sale, the chief executive officer now directly owns 195,686 shares in the company, valued at $25,141,737.28. The trade was a 2.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Michael Burkes Brophy sold 608 shares of Natera stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $120.76, for a total transaction of $73,422.08. Following the completion of the transaction, the chief financial officer now directly owns 74,014 shares in the company, valued at approximately $8,937,930.64. This trade represents a 0.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 36,821 shares of company stock valued at $4,776,878 in the last ninety days. Corporate insiders own 7.60% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.